We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

034730:KRXSK Inc. Analysis

Data as of 2026-06-13 - not real-time

₩593,000.00

Latest Price

7/10Risk

Risk Level: Medium

Executive Summary

SK Inc. is trading comfortably above its 20‑day simple moving average, indicating short‑term momentum support, while the 50‑day and 200‑day averages remain well below the current price, underscoring a bullish price trend.
The 14‑day RSI sits in a moderate zone, suggesting the stock is neither overbought nor oversold, and the MACD histogram is negative, flagging short‑term bearish momentum that tempers the longer‑term bullish bias.
Support sits near the 492,000 KRW level and resistance near 719,000 KRW, placing the market price squarely within a wide upside corridor, reinforced by a high 30‑day volatility of roughly 79% and a beta above 1.5, which together signal elevated market‑price sensitivity.
Fundamentally, the company boasts a very low trailing P/E relative to its industry peers, a solid dividend yield of 1.35% with a modest payout ratio, and a strong‑buy consensus from analysts, all of which lend weight to a fundamentally attractive profile despite the technical headwinds.

Market Outlook

Short Term

< 1 year
Neutral
Model confidence: 7/10

Key Factors

  • negative MACD histogram indicating near‑term bearish pressure
  • moderate RSI suggesting limited upside in the immediate horizon
  • decreasing volume trend reducing short‑term liquidity confidence

Medium Term

1–3 years
Positive
Model confidence: 8/10

Key Factors

  • price positioned above key support and well below resistance
  • bullish 20‑day SMA alignment and strong fundamental earnings yield
  • industry‑average P/E gap providing valuation upside

Long Term

> 3 years
Positive
Model confidence: 8/10

Key Factors

  • sustained dividend yield with low payout ratio supporting cash flow stability
  • diversified conglomerate exposure mitigating sector‑specific downturns
  • analyst consensus of strong‑buy and forward P/E indicating long‑term earnings potential

Key Metrics & Analysis

Financial Health

Revenue Growth18.90%
Profit Margin2.05%
P/E Ratio6.4
ROE11.91%
ROA1.24%
Debt/Equity79.56
Op. Cash Flow₩6967.6B
Free Cash Flow₩4269.7B
Industry P/E30.6

Technical Analysis

TrendBullish
RSI54.4
Support₩492,000.00
Resistance₩719,000.00
MA 20₩602,200.00
MA 50₩482,740.00
MA 200₩323,618.00
MACDBearish
VolumeDecreasing
Fear & Greed Index89.86

Valuation

Fair Value₩1,344,239.91
Target Price₩685,416.70
Upside/Downside15.58%
GradeFair
TypeBlend
Dividend Yield1.35%

Risk Assessment

Beta1.30
Volatility78.86%
Sector RiskMedium
Reg. RiskHigh
Geo RiskMedium
Currency RiskMedium
Liquidity RiskMedium

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.